Comparative Pharmacology
Head-to-head clinical analysis: DURAGESIC 50 versus EMBEDA.
Head-to-head clinical analysis: DURAGESIC 50 versus EMBEDA.
DURAGESIC-50 vs EMBEDA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fentanyl is a potent synthetic opioid agonist primarily at μ-opioid receptors, with additional weak affinity for κ- and δ-opioid receptors. It increases potassium conductance and decreases calcium influx, leading to hyperpolarization and reduced neurotransmitter release, resulting in analgesia and sedation.
EMBEDA is a combination of morphine sulfate, a full opioid agonist, and naltrexone hydrochloride, an opioid antagonist. Morphine binds to mu-opioid receptors in the CNS, altering pain perception and response. Naltrexone is sequestered in the core and is released if the pellets are crushed or chewed, potentially precipitating withdrawal or blockade of morphine effects.
Apply one 50 mcg/h transdermal system every 72 hours; initiate at 25 mcg/h in opioid-naive patients; titrate based on response and tolerability.
1 to 2 capsules orally every 12 hours, titrated to pain relief. Maximum daily dose: 100 mg naltrexone (equivalent to 100 mg morphine). Capsules must be swallowed whole.
None Documented
None Documented
Mean terminal elimination half-life 20–27 h (range 13–40 h). Prolonged with hepatic impairment, elderly, or obesity. Clinical context: Requires ~5 days to reach steady state; accumulation risk with continuous use.
Morphine: 2-4 hours; naltrexone: 4-13 hours (active metabolite 6β-naltrexol: 12-18 hours). Clinically, morphine's half-life is prolonged in hepatic or renal impairment.
Primarily renal: ~75% as metabolites (mostly norfentanyl, <10% unchanged fentanyl); ~9% biliary/fecal; <10% excreted in urine as unchanged drug.
Renal: ~60% (morphine), ~20% (naltrexone, in urine as unchanged drug and metabolites); biliary/fecal: ~10% (morphine-3-glucuronide and other metabolites).
Category C
Category C
Opioid Analgesic
Opioid Analgesic